Our Pipeline

Apellis’ efforts are focused on developing complement immunotherapies. We believe that this approach can result in broad inhibition of the principal pathways of the complement system and has the potential to effectively control a broad range of serious diseases.

The safety and efficacy of the agents for the indications under investigation have not been established. There is no guarantee that the outcome of these studies will result in approval by a Health Authority.

RARE DISEASE

Product
Disease
Pre-Clinical
Phase I
Phase II
Phase III
Launch
Systemic pegcetacoplan*
PNH
Launch Marketed in the US
IC-MPGN /C3G
Phase II Initiate Ph 3 in 1H'22
ALS
Phase II Complete enrollment in 1H'22
CAD
Phase II Initiate Ph 3 in 1H'22
HSCT -TMA
Phase II
siRNA + pegcetacoplan**
Existing + new indications
Pre-clinical IND in 1H'23

Ophthalmology

Product
Disease
Pre-Clinical
Phase I
Phase II
Phase III
Launch
Intravitreal pegcetacoplan
GA
Phase III Submit U.S. NDA in 2Q‘22
APL-2006
GA & Wet AMD
Pre-clinical IND in 1H’23
Gene therapies
Wet AMD, Intermediate AMD & GA
Pre-clinical

Neurology

Product
Disease
Pre-Clinical
Phase I
Phase II
Phase III
Launch
APL-1030
Undisclosed
Pre-clinical IND in 2H‘22
Brain Shuttle
Undisclosed
Pre-clinical
Gene therapies
Undisclosed
Pre-clinical

Multiple therapeutic areas

Product
Disease
Pre-Clinical
Phase I
Phase II
Phase III
Launch
Systemic pegcetacoplan
Control of host attack for gene therapies
Pre-clinical Pre-clinical data in 1H’22
Oral alternative pathway inhibitor
Mild C3G and other indications
Pre-clinical
Gene-edited therapies (Beam)
Undisclosed
Pre-clinical

*Sobi has global co-development and ex-U.S. commercialization rights for systemic pegcetacoplan **Initial IND for siRNA ***Pending regulattory feedback Potential to be registrational

To learn more about Apellis clinical trials go to clinicaltrials.gov

You are now leaving ApellisMedicalHub.com

You are about to leave ApellisMedicalHub.com to visit a third-party website. We recommend reviewing the privacy policy and terms & conditions of any site you visit, as Apellis Pharmaceuticals, Inc. is not responsible for their content.